No CrossRef data available.
Article contents
The Disappointment of the Biosimilar
Published online by Cambridge University Press: 01 January 2021
Abstract
An abstract is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
![Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'](https://static.cambridge.org/content/id/urn%3Acambridge.org%3Aid%3Aarticle%3AS1073110500022993/resource/name/firstPage-S1073110500022993a.jpg)
- Type
- Independent Articles: Commentary
- Information
- Copyright
- Copyright © American Society of Law, Medicine and Ethics 2018
References
Herber, M., “The first drug with a $1 million price tag is already on the market,” Forbes, May 1, 2018, available at <https://www.forbes.com/sites/matthewherper/2012/05/01/the-first-drug-with-a-1-million-price-tag-is-already-on-the-market/#7bb318baabde> (last visited August 2, 2018).+(last+visited+August+2,+2018).>Google Scholar
Diependaele, L. et al., “Similar or the Same? Why Biosimilars are not the Solution,” Journal of Law, Medicine & Ethics 46, no. 3 (2018): 776-790.CrossRefGoogle Scholar
Beran, D., Hirsch, I. B., and Yudkin, J. S., “Why are we Failing to Address the Issue of Access to Insulin? A National and Global Perspective,” Diabetes Care 41, no. 6 (2018): 1125-1131.Google Scholar
Heinemann, L., “Biosimilar Insulins: How will this Story Evolve?” Diabetes Technology & Therapeutics 14 (2012):986-988.Google Scholar
Greene, J.A., Generic: The Unbranding of Modern Medicine (Baltimore: Johns Hopkins University Press, 2014).Google Scholar
Engelberg, A.B., “Special Patent Provisions for Pharmaceuticals: Have They Outlived Their Usefulness,” Specialty Law Digest: Health Care Law 258 (2000):9-48.Google Scholar